AI assistant
ARIX BIOSCIENCE PLC — Regulatory Filings 2017
Dec 22, 2017
4968_rns_2017-12-22_eff1883f-c6d6-475f-8c0d-a04bf6a02bdb.html
Regulatory Filings
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 1503A
Arix Bioscience Plc
22 December 2017
22 December 2017
Arix Bioscience plc
Issue of Ordinary Shares, Total Voting Rights and Director/PDMR Shareholding Notifications
Arix Bioscience plc (the "Company") announces that it has allotted New Ordinary Shares to two non-executive directors, in accordance with the compensation agreed at their appointments, as follows:
| Name of executive director | Number of shares allotted | ||
| Meghan FitzGerald | 30,344 | ||
| Giles Kerr | 31,663 |
Application has been made for the 62,007 New Ordinary Shares to be admitted to the standard segment of the Official List and to trading on the Main Market of the London Stock Exchange. The new Ordinary Shares will rank pari passu with the existing ordinary shares and it is expected that admission of these New Ordinary Shares will take place at 8.00 a.m. on 28 December 2017.
Following the issue of 62,007 shares the Company will have a total of 96,153,090 ordinary shares of £0.00001 each in issue and a total number of voting rights in the Company of 96,153,090. The above figure of 96,153,090 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
| PDMR DEALING NOTIFICATION | |||
| Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | |||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Meghan FitzGerald | |
| 2 | Reason for the notification | ||
| a) | Position / status | Non Executive Director | |
| b) | Initial notification / Amendment |
Initial Notification | |
| 3 | Details of issuer | ||
| a) | Name | Arix Bioscience plc | |
| b) | LEI | 213800OVT3AHQCXNIX43 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of Arix Bioscience plc | |
| Identification code | GB00BD045071 | ||
| b) | Nature of the transaction | Award of Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £1.895 | 30,344 | ||
| d) | Aggregated information | Aggregated price | Aggregated volume |
| N/A (single transaction) | N/A (single transaction) | ||
| e) | Date of the transaction | 21 December 2017 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| PDMR DEALING NOTIFICATION | |||
| Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | |||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Giles Kerr | |
| 2 | Reason for the notification | ||
| a) | Position / status | Non Executive Director | |
| b) | Initial notification / Amendment |
Initial Notification | |
| 3 | Details of issuer | ||
| a) | Name | Arix Bioscience plc | |
| b) | LEI | 213800OVT3AHQCXNIX43 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of Arix Bioscience plc | |
| Identification code | GB00BD045071 | ||
| b) | Nature of the transaction | Award of Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £1.895 | 31,663 | ||
| d) | Aggregated information | Aggregated price | Aggregated volume |
| N/A (single transaction) | N/A (single transaction) | ||
| e) | Date of the transaction | 21 December 2017 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
For further information:
James Rawlingson Chief Financial Officer +44 (0)207 290 1050
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFMMZZGMNGNZZ